Urology Doctors in North Charleston, SC Accepting Medicare

7 Urology doctors found. Showing 1 - 7

Dr. Nelson Randolph Ploch, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2890 Tricom Street, North Charleston, SC 29406 Phone: 843-797-6600    Fax: 843-820-1440

Dr. Samuel Walker Nickles, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2890 Tricom St, North Charleston, SC 29406 Phone: 843-797-6600    Fax: 843-820-1440

Dr. Taylor B Vaughan, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2890 Tricom St, North Charleston, SC 29406 Phone: 843-797-6600    Fax: 843-820-1440

Dr. Frederick James Goulding, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 2890 Tricom Street, North Charleston, SC 29406 Phone: 843-797-6600    Fax: 843-820-1440

Dr. Theodore Edward Brisson, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2890 Tricom Street, North Charleston, SC 29406 Phone: 843-797-6600    Fax: 843-820-1440

Dr. Kelly Elaine Shaffer, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2687 Lake Park Dr, North Charleston, SC 29406 Phone: 843-572-1010    Fax: 843-569-1719

Dr. Marshall Scott Wingo, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2687 Lake Park Dr, North Charleston, SC 29406 Phone: 843-572-1010    Fax: 843-569-1719

News Archive

Perrigo re-launches shipments of Guaifenesin 600mg Extended-Release tablets

Perrigo Company plc announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg Extended-Release tablets.

Hospital performance at mercy of stroke severity

Accounting for stroke severity has a major impact on the accuracy of models that rank the performance of hospitals in acute stroke care, show findings published in JAMA.

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

CRG, Illumina partner for large-scale analysis of genetic variation and function

The Centre for Genomic Regulation (CRG) has recently signed a year-long collaboration agreement with Illumina, a leading developer and manufacturer of life sciences tools and integrated systems for large-scale analysis of genetic variation and function.

Read more Medical News

› Verified 4 days ago